- Home
- SVA vs SNN Comparison
SVA vs SNN Comparison
Compare SVA & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVA
- SNN
- Stock Information
- Founded
- SVA N/A
- SNN 1856
- Country
- SVA
- SNN United Kingdom
- Employees
- SVA 3261
- SNN N/A
- Industry
- SVA
- SNN Industrial Specialties
- Sector
- SVA
- SNN Health Care
- Exchange
- SVA NYSE
- SNN Nasdaq
- Market Cap
- SVA N/A
- SNN 12.4B
- IPO Year
- SVA N/A
- SNN 1999
- Fundamental
- Price
- SVA $6.47
- SNN $29.44
- Analyst Decision
- SVA
- SNN Strong Buy
- Analyst Count
- SVA 0
- SNN 1
- Target Price
- SVA N/A
- SNN N/A
- AVG Volume (30 Days)
- SVA N/A
- SNN 674.7K
- Earning Date
- SVA N/A
- SNN 08-01-2024
- Dividend Yield
- SVA N/A
- SNN 2.55%
- EPS Growth
- SVA N/A
- SNN 39.77
- EPS
- SVA N/A
- SNN 0.35
- Revenue
- SVA N/A
- SNN $5,642,000,000.00
- Revenue This Year
- SVA N/A
- SNN $6.92
- Revenue Next Year
- SVA N/A
- SNN $5.43
- P/E Ratio
- SVA N/A
- SNN $41.81
- Revenue Growth
- SVA N/A
- SNN 5.48
- 52 Week Low
- SVA N/A
- SNN $21.53
- 52 Week High
- SVA N/A
- SNN $31.72
- Technical
- Relative Strength Index (RSI)
- SVA N/A
- SNN 46.87
- Support Level
- SVA N/A
- SNN $28.26
- Resistance Level
- SVA N/A
- SNN $29.64
- Average True Range (ATR)
- SVA 0.00
- SNN 0.36
- MACD
- SVA 0.00
- SNN 0.05
- Stochastic Oscillator
- SVA 0.00
- SNN 58.65
About SVA SINOVAC BIOTECH LTD
Sinovac Biotech Ltd is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including, without limitation, hepatitis A, hepatitis B, hand foot and mouth disease (HFMD) caused by EV71, seasonal influenza, H5N1 and H1N1 pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella and mumps.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.